New Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

After a full session in September, the next explicyte shuttle – anti-PD1 / anti-PDL1 syngeneic mouse models – is scheduled for the 25th of October.

The explicyte shuttle is a standardized study protocol in which you can include experimental groups in an already programmed study. Explicyte will cover the costs of the vehicle control group + the standard reference and sponsor will only cover its experimental groups.

In Vivo Syngeneic Mouse Tumor Models – CT26 And MC38 – With Differential Sensitivity To PD-1 / PD-L1 Blockade

  • Strains: Balb/c or C57BL/6 mice
  • Readouts: Tumor growth / Body-weight / Survival
  • Standard reference : PD-1 or  PDL-1 monoclonal antibodies
  • Experimental conditions: At least 10 animals per group
  • Turnaround time: 11-13 weeks

Immune cell profiling at the tumor site  of CT-26 tumor-bearing mice. Tumors from CT-26 tumor bearing mice were harvested, and stained for CD4 followed by intracellular anti-FoxP3 staining, or CD11b and Gr1. Flow cytometric analysis revealed the presence of immunosuppressive cell subsets including Treg cells (CD4+/FoxP3+ ) and myeloid cells (CD11b+/Gr1+high) within the tumor.